News

The randomised, double-blind, placebo-controlled study will evaluate MORAb-004, a monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1). Using an adaptive design, the trial will enrol up

The new service, which utilizes commercial off-the-shelf equipment, can deliver a DNA profile from evidentiary samples in under 90 minutes and even allows for DNA to be used

Stem-Kine will be marketed under the name SK Plus in Taiwan. RBC Life Sciences CEO Clinton Howard said Stem-Kine was developed as optimum nourishment to bone marrow, enabling

The container, which leverages the company’s Pro-Tectic temperature storage technology and requires no dry ice, PCMs or other consumables, can be recharged using standard AC electrical power. Cool

As per the agreement, Janssen gained non-exclusive license and other rights to certain Acuform patents and in return Depomed will earn $10m upfront payment and low single digit

Merck is planning to file applications for vorapaxar, an investigational anti-thrombotic medicine in the US and the European Union in 2013 following the review of the clinical trial

Phase III randomised, open-label EMILIA study has met co-primary efficacy endpoints of overall survival and progression-free survival (PFS). The study showed that trastuzumab emtansine (T-DM1) significantly extended the

Under the agreement, Mediterranea gained rights to sell DiaSys’ equipments in Singapore, Malaysia, Indonesia, Vietnam, and Cambodia. Mediterranea CEO Livio Orsini Gravina said the company understands that increased

Zyclara can detect and eliminate subclinical as well as clinical AK lesions on large areas of the skin. Zyclara has shown to be an effective therapy in eliminating